The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir

Abstract

SUMMARY Background

Updated thresholds for serum alanine aminotransferase level in a large‐scale population study composed of 34 346 subjects

“…Third, for patients who received adequate anti‐viral therapy, serum ALT levels often decreased to levels below 30 U/L when there was sustained virological response . Fourth, in the current study, majority of subjects who had serum ALT levels within the ULN by current threshold were still unhealthy.…”

Treatment cessation in noncirrhotic, e‐antigen negative chronic hepatitis B is safe and effective following prolonged anti‐viral suppression with nucleosides/nucleotides

“…34 In addition, the size of our cohort and small number of patients in each treatment group limited the degree to which we could simultaneously investigate multiple factors predictive of a composite relapse following anti-viral discontinuation. In particular, adequate comparison of post-treatment outcomes between individual anti-viral agents and whether newer first-line agents entecavir and tenofovir are superior to lamivudine and adefovir, such as has been recently suggested, [34][35][36] was not possible. Larger cohorts will help to identify additional factors predictive of a sustained response.…”

“…Following cessation of anti-viral therapy, 21 (63%) patients had a viral relapse, 16 (48%) had a biochemical relapse and 11 patients (33%) met the primary composite end point of a biochemical and virological relapse requiring retreatment. A total of 16 patients were ultimately restarted on treatment, leaving 17 (52%) patients who remained treatment-free in the follow-up period, a median of 36 [24][25][26][27][28][29][30][31][32][33][34][35][36]…”

Long-Term Efficacy of Entecavir Plus Adefovir Combination Therapy versus Entecavir Monotherapy in Adefovir Refractory Chronic Hepatitis B Patients with Prior Lamivudine Resistance

“…Reijnders et al [27] reported that ETV was effective in ADV-experienced patients including those with ADV resistance and that there was no difference in the efficacy of ETV between LAM-naive and -experienced patients without a history of LAM resistance. Similarly, Sheen et al [28] demonstrated that, by 12 months after switching to ETV treatment, complete viral suppression (serum HBV DNA <100 IU/ml) was achieved in the majority of both LAM-experienced and -naive patients (68%) who had a suboptimal response to ADV. However, in LAM-resistant patients, ETV monotherapy reduced the probability of achieving a virologic response.…”